• citation needed] CETP inhibitors inhibit cholesterylester transfer protein (CETP), which normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). (wikipedia.org)
  • Also, he said, the ACCELERATE study, which looked at the cholesterol esterase transfer protein (CETP) inhibitor evacetrapib (Eli Lilly), suggested that raising HDL-C and improving cholesterol efflux (the first step in cholesterol transport) did not decrease CV risk. (medscape.com)
  • Two more CETP inhibitors are still in development, Merck's anacetrapib and evacetrapib from Eli Lilly. (chemistryworld.com)
  • However, there is another question overshadowing the CETP inhibitors - how much does raising your HDL levels help to protect your heart? (chemistryworld.com)
  • Two other drugs in the same class as evacetrapib, known as CETP inhibitors, have also failed: One, which lowered LDL levels by only 20 percent, had toxic side effects. (healthimpactnews.com)
  • Over the past decade, five different experimental drugs known as CETP inhibitors have been tested in large clinical trials in people with low HDL. (harvard.edu)
  • The hypothesis was not confirmed by large clinical trials (with niacin, with CETP inhibitors), even though there was an increase of serum HDL-C level detected. (kardiologickarevue.cz)
  • Ale túto hypotézu nepotvrdili veľké klinické štúdie (s niacínom, s CETP inhibítormi), hoci došlo k zvýšeniu sérovej hladiny HDL-c. (kardiologickarevue.cz)
  • Ale túto hypotézu nepotvrdili v nedávnych rokoch randomizované veľké klinické štúdie (liečba niacínom, inhibítormi CETP), ktoré dokázali významne zvýšiť koncentráciu HDL-c v sére, čo však neprinieslo očakávaný klinický benefit [3- 7]. (kardiologickarevue.cz)
  • Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe. (citeline.com)
  • The LDL:HDL ratio in humans is set mainly by CETP activity, which exchanges cholesteryl esters for triglycerides across lipoprotein fractions to raise LDL and lower HDL as CETP activity increases. (biomedcentral.com)
  • Unlike humans, wild-type mice do not express catalytically active CETP and have HDL as their major lipoprotein fraction. (biomedcentral.com)
  • Low CETP activity is associated with better cardiovascular health, due to decreased LDL and increased HDL, which may also improve brain health. (biomedcentral.com)
  • and 3) describing the functions of cholesteryl ester transfer protein (CETP) in regulating the LDL:HDL ratio in humans, including therapeutic strategies targeting CETP. (biomedcentral.com)
  • The literature search strategy used focused on the search terms AD, VCID, LDL, HDL, and CETP to identify primary papers and review articles in PubMed and Medline within the last 25 years. (biomedcentral.com)
  • http://expertscape.com/au/lipoproteins%2C+hdl/Kypreos%2C+K+E-Apolipoprotein A1, ranks in the top 0.83% worldwide among 13,490 published authors from 2007 through 2018. (kyriakoskypreos.com)
  • The Residual Risk Reduction Initiative (R 3 i) has previously highlighted atherogenic dyslipidaemia, defined as the imbalance between proatherogenic triglyceride-rich apolipoprotein B-containing-lipoproteins and antiatherogenic apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL), as an important modifiable contributor to lipid-related residual cardiovascular risk, especially in insulin-resistant conditions. (biomedcentral.com)
  • Indeed, this scenario is illustrated by the INTERHEART study, a global case-control study which highlighted the relevance of both atherogenic apolipoprotein (apo) B100-containing lipoproteins and potentially atheroprotective apoA-I containing lipoproteins, such as high-density lipoproteins (HDL), to coronary risk. (biomedcentral.com)
  • Humans have a peripheral lipoprotein profile where low-density lipoproteins (LDL) represent the dominant lipoprotein fraction and high-density lipoproteins (HDL) represent a minor lipoprotein fraction. (biomedcentral.com)
  • Drug maker Eli Lilly halted a trial of evacetrapib in 2015 based on a lack of reduction in heart attack, stroke, the need for surgery or hospitalization, or the amount of time high-risk patients survived to cardiovascular death, researchers said in a presentation at the American College of Cardiology's 65th Annual Scientific Session . (upi.com)
  • Eli Lilly and Co.'s evacetrapib (ev-uh-SET-ruh-pib) showed good effects on cholesterol in a mid-stage study of 400 people testing the drug by itself or with other cholesterol-lowering drugs. (rdworldonline.com)
  • In 2016 it was announced that a new drug that Eli Lilly was developing to lower cholesterol was abandoned because it offered no improvement in heart health. (healthimpactnews.com)
  • A separate study found that, compared with placebo or statin monotherapy, evacetrapib as monotherapy or in combination with statins increased HDL-C levels and decreased LDL-C levels. (medscape.com)
  • The detailed results from the FOURIER outcomes trial were presented at the American College of Cardiology's 66th Annual Scientific Session Friday, March 17 in Washington, D.C.According to the new data, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. (kyriakoskypreos.com)
  • Sales to date from this one particular cholesterol-lowering statin drug have exceeded $140 billion. (healthimpactnews.com)
  • However, our bodies need cholesterol, and a whole range of side effects are now known to accompany statin drug usage, such as neurological diseases , breast cancer , liver injury, memory loss, diabetes , and muscle damage. (healthimpactnews.com)
  • Those of us in the Alternative Media have been exposing the Statin Scam and Cholesterol Myth for many years now. (healthimpactnews.com)
  • Addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe are all options for combination with a statin to further reduce non-HDL cholesterol, although lacking in hard evidence for cardiovascular outcome benefits. (biomedcentral.com)
  • Eligible patients were receiving guideline-directed lipid-lowering therapy or could not receive statin therapy without adverse effects and had low-density lipoprotein (LDL) cholesterol levels of 100 mg per deciliter or lower. (bvsalud.org)
  • The document also reported that there are several causes of low HDL cholesterol levels and that a number of these-including type II diabetes, overweight, obesity, elevated triglycerides (TGs), and a lack of physical activity-are associated with insulin resistance . (medscape.com)
  • The ATP III reported, "When a low HDL cholesterol is associated with high triglycerides (200-499 mg/dL), secondary priority goes to achieving the non-HDL cholesterol goal. (medscape.com)
  • It suggests that the association between future CV risk and levels of HDL-C, as currently measured in practice, is modified by LDL cholesterol and triglycerides . (medscape.com)
  • Findings from the original Framingham cohort helped establish that HDL-C levels, by themselves, are inversely correlated with CV risk, but their triglycerides weren't consistently measured, according to the report. (medscape.com)
  • Elevated HDL-C was associated with a 20% to 40% drop in CV risk compared with isolated low HDL-C. But there was no significant risk effect when both triglycerides and LDL were 100 mg/dL or higher. (medscape.com)
  • The interior of a lipoprotein-called the lipid core-carries the triglycerides and cholesterol esters, both of which are insoluble in water. (pressbooks.pub)
  • That's especially true for people who have high triglycerides, which tend to go hand-in-hand with low HDL levels," says Dr. Plutzky. (harvard.edu)
  • These drugs have generally failed in clinical trials, either causing a marked increase in deaths (torcetrapib), or having no meaningful clinical improvement despite HDL increases (dalcetrapib, evacetrapib). (wikipedia.org)
  • needs update] Anacetrapib Dalcetrapib Evacetrapib Obicetrapib Torcetrapib Tall AR (March 2007). (wikipedia.org)
  • Of the other two drugs, dalcetrapib was as ineffective as evacetrapib at preventing cardiovascular events, while torcetrapib increased risk. (upi.com)
  • In a study published in 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology , they found that two of the experimental drugs, evacetrapib and torcetrapib, tended to raise the subtypes of HDL that are not associated with cardiovascular benefit. (harvard.edu)
  • Inhibition of this process results in higher HDL levels and reduces LDL levels. (wikipedia.org)
  • Past observational studies in large groups of people have suggested that those with higher HDL levels (above 40 mg/dL for men and 50 mg/dL for women) tend to have fewer heart attacks. (harvard.edu)
  • Genetic association study of APOA1/C3/A4/A5 gene cluster and haplotypes on triglyceride and HDL cholesterol in a community-based population. (medscape.com)
  • However, the high-HDL advantage is erased if LDL-C and triglyceride levels exceed 100 mg/dL. (medscape.com)
  • The serum PK level was positively correlated with the serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) levels. (bvsalud.org)
  • METHODS: In a multinational, double-blind, randomized, controlled trial, we assigned patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia (triglyceride level, 200 to 499 mg per deciliter), and high-density lipoprotein (HDL) cholesterol levels of 40 mg per deciliter or lower to receive pemafibrate (0.2-mg tablets twice daily) or matching placebo. (bvsalud.org)
  • RESULTS: Among 10,497 patients (66.9% with previous cardiovascular disease), the median baseline fasting triglyceride level was 271 mg per deciliter, HDL cholesterol level 33 mg per deciliter, and LDL cholesterol level 78 mg per deciliter. (bvsalud.org)
  • Tangier disease, familial hypoalphalipoproteinemia and familial deficiency of lecithin cholesterol acyltransferase deficiency]. (medscape.com)
  • The failure of dalcetrapib, a drug from Roche designed to raise HDL, or 'good', cholesterol, has turned the spotlight again on such drugs. (chemistryworld.com)
  • The HDL elevation is substantially lower with dalcetrapib and, more importantly, there was no LDL ['bad' cholesterol] reduction. (chemistryworld.com)
  • Maybe that's because they increased the wrong type of HDL, according to researchers at the Harvard T.H. Chan School of Public Health, who scrutinized 16 of the 200-plus different subtypes of HDL. (harvard.edu)
  • Evacetrapib is the third drug in a group called cholesteryl ester transfer protein inhibitors meant to disrupt the process turning HDL cholesterol into LDL, or "bad," cholesterol. (upi.com)
  • Substantial evidence supports the use of statins in the secondary prevention of CAD, and the efficacy of statins has recently been extended to include primary prevention of CAD in patients with average cholesterol levels. (medscape.com)
  • All patients already being treated for other conditions, including with statins or other drugs to lower cholesterol, continued with their regular drug regimens. (upi.com)
  • Rather, our data suggest that improving HDL particle functionality is the proper strategy and of course requires a deep understanding of the structure-function relationship of HDL. (kyriakoskypreos.com)
  • LDL is a pretty homogeneous particle, whereas HDL is a symphony of different types of molecule, where the particles have different lipid cargo, different protein cargo and composition, but we lump them all together. (chemistryworld.com)
  • Our manuscript 'High-Density Lipoprotein (HDL) metabolism and bone mass' recently accepted for publication in the Journal of Endocrinology (IF=4.71, Official Journal of the Society for Endocrinology) has been selected to be featured in the journal's educational resource - Journal Based Learning (JBL). (kyriakoskypreos.com)
  • BACKGROUND: Recent evidence has revealed that circulating coagulation factor prekallikrein (PK), an important part of the kallikrein-kinin system, regulates cholesterol metabolism, but the association between serum PK and lipid levels is unclear. (bvsalud.org)
  • These results stimulated analysis of HDL particles and their pleiotropic actions were discovered: small and more dense HDL particles had greater cholesterol efflux, together with anti-inflammatory and anti-oxidative activities, than the larger and less dense HDL particles. (kardiologickarevue.cz)
  • Obicetrapib (TA-8995, AMG-899), Phase II results reported in 2015, Drugs in this class substantially increase HDL cholesterol, lower LDL cholesterol, and enhance reverse cholesterol transport. (wikipedia.org)
  • While we still believe that HDL-C plays a pivotal role in reverse cholesterol transport, we have yet to prove that either raising HDL-C levels or improving its function reduces CVD risk," he said. (medscape.com)
  • But it turns out that not all HDL particles perform this function, which is known as reverse cholesterol transport. (harvard.edu)
  • Some types of HDL are indifferent to cholesterol, and others actually block the process of reverse cholesterol transport. (harvard.edu)
  • This was the background of 'HDL - hypothesis': that with an increase of serum HDL-C levels, we can reduce cardiovascular morbidity and mortality. (kardiologickarevue.cz)
  • The phase 3 randomized trial for evacetrapib enrolled 12,000 patients around the world at high risk for cardiovascular events, treating them with 130 milligrams of the drug or a placebo daily for 18 months. (upi.com)
  • While the researchers said they were surprised and disappointed by the trial's results, future studies focusing on other groups of patients need to be conducted, perhaps with those at lower risk for cardiovascular events or who are not already being treated with other cholesterol drugs. (upi.com)
  • In patients with an increase of small and dense HDL particles in serum, there was lower risk of ischaemic heart dis-ease, carotid atherosclerosis and of cardiovascular events and death. (kardiologickarevue.cz)
  • Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? (medscape.com)
  • FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) provided definitive evidence of the outcomes benefits of lowering plasma levels of low-density lipoprotein cholesterol (LDL-C) beyond current goals. (eas-society.org)
  • A nonlinear relationship was observed between serum PK and high-density lipoprotein cholesterol (HDL-C) levels. (bvsalud.org)
  • Hackethal V. Framingham: Low HDL, in Isolation, Not a CV Risk Predictor. (medscape.com)
  • FRAMINGHAM, MA - Long-term findings from a famous cohort study challenge the idea that low HDL-cholesterol levels predict raised cardiovascular risk independently of other blood lipid markers and add to doubts about HDL-C per se as a target for therapy [ 1 ] . (medscape.com)
  • Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. (medscape.com)
  • The Framingham Heart Study discovered that people with high serum HDL-C levels usually have low cardiovascular risk. (kardiologickarevue.cz)
  • The Journal of Lipid Research, the official lipidology journal of ASBMB, yesterday published our work on the "Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity" Apolipoprotein C3 (APOC3) is a small glycoprotein in blood, secreted by the liver and intestine. (kyriakoskypreos.com)
  • Often times I felt very lonely going against the prevailing view and the billions of dollars invested in HDL-C raising drugs. (kyriakoskypreos.com)
  • Moreover, Prof. Kypreos' work on:-High Density Lipoprotein (HDL) ranks in the top 0.29% worldwide among 60,349 published authors from 2007 through 2018. (kyriakoskypreos.com)
  • CHICAGO, April 5 (UPI) -- A drug that lowers bad cholesterol and significantly increases good cholesterol, which doctors expected would increase cardiovascular health, failed to reduce rates of adverse health events in a large clinical trial, according to researchers. (upi.com)
  • 60% of calories), and certain agents (such as progestational drugs, anabolic steroids, and beta blockers) as causes of low HDL levels. (medscape.com)
  • Furthermore, currently available drugs do not robustly raise HDL cholesterol. (medscape.com)
  • According to the ATP III, if a patient's TG levels are below 200 mg/dL (isolated low HDL cholesterol), the administration of drugs that increase HDL (fibrates or nicotinic acid) can be considered. (medscape.com)
  • Cholesterol-lowering drugs are the best-selling drugs of all time. (healthimpactnews.com)
  • There is one major flaw with cholesterol-lowering drugs: they neither improve heart health nor prolong life according to scientific studies. (healthimpactnews.com)
  • Since blockbuster cholesterol-lowering drugs like Lipitor now have expired patents, millions of dollars have been spent in research to develop new cholesterol-lowering drugs. (healthimpactnews.com)
  • When they decided to develop a new class of cholesterol drugs to increase HDL while decreasing LDL they had to stop all clinical trials. (sallyanncreed.co.za)
  • Hopes for a precision approach for the vast cardiovascular disease population live on - past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL. (citeline.com)
  • For some decades there has been an interest in investigat-ing the role of HDL particles in cardiovascular dis-eases. (kardiologickarevue.cz)
  • In this paper, we present data about subfractions of HDL particles in heart failure (782 patient with systolic heart failure and 1,004 patients with diastolic heart failure): 1. (kardiologickarevue.cz)
  • 2. The presence of small HDL particles in serum of patients with heart failure improved the patients' prognosis, as these patients suffered from less cardivascular events dur-ing the follow-up. (kardiologickarevue.cz)
  • 20%), the LDL goal is under 100 mg/dL, and the goal for non-HDL cholesterol (LDL plus very-low-density lipoprotein [VLDL]) is below 130 mg/dL. (medscape.com)
  • The gene in study is just one genetic marker out of many, and while no effect was seen on the risk of coronary disease or MI, it may be that it is the 'wrong' type of HDL. (chemistryworld.com)
  • Rare genetic variations known to cause high HDL but also increase heart disease risk didn't explain these paradoxical findings. (harvard.edu)
  • 1 Sekar Kathiresan, director of preventive cardiology at Massachusetts General Hospital, US, and one of the authors of the study, explains that about 2.5% of the population carry the endothelial lipase gene and this boosts HDL cholesterol by about six points. (chemistryworld.com)
  • As HDL has potent beneficial effects on endothelial cells, the naturally high HDL levels in mice protect them from vascular disorders, likely including VCID. (biomedcentral.com)
  • Therefore, the presence of HDL subfractions is a marker of residual cardiovascular risk in heart failure patients. (kardiologickarevue.cz)
  • Who Suffers From Lilly's Evacetrapib Failure? (citeline.com)
  • This finding of a low high-density lipoprotein (HDL) cholesterol level can be useful as an independent factor in assessing coronary artery disease (CAD) risk and further management. (medscape.com)
  • With regard to HA, the ATP III report stated, "Low HDL cholesterol is a strong independent predictor of CHD [coronary heart disease]. (medscape.com)
  • Since 2006 I have been preaching that, based on our data and critical review of published literature, simply raising HDL cholesterol (HDL-C) levels is a failed strategy in the fight against coronary heart disease. (kyriakoskypreos.com)
  • Therapy with lipid-lowering agents should be a component of multiple risk factor intervention and is indicated in primary prevention as an adjunct to diet therapy when the response to a diet restricted in saturated fat and cholesterol has been inadequate. (medscape.com)
  • CV risk was sharply elevated among participants with low HDL-C when levels of the other markers were not optimal, compared with those with isolated HDL-C, even after adjustment for age at initial lipid testing, sex, diabetes, hypertension , and smoking. (medscape.com)
  • The R 3 i believes that monitoring of non-HDL cholesterol provides a simple, practical tool for treatment decisions regarding the management of lipid-related residual cardiovascular risk. (biomedcentral.com)
  • Overall, patients treated with the drug had 37 percent lower levels of bad cholesterol and 130 percent higher levels of good cholesterol, but researchers report there was no difference in cardiovascular endpoints between the treatment and placebo groups. (upi.com)
  • While evacetrapib posed no safety concerns and caused no major side effects, researchers said the trial suggests the benefits of HDL cholesterol, referred to as "good" cholesterol, have been overestimated by doctors and scientists. (upi.com)
  • That study suggests that the correct assay to measure cholesterol function may not even be being used, according to Miller. (medscape.com)
  • A very low or very high HDL value should be a red flag warning to double down on your efforts to dodge heart disease, an editorial accompanying the JAMA Cardiology study suggests. (harvard.edu)
  • Recent studies show an association between elevated plasma LDL, a well-known cardiovascular risk factor, and a higher risk of AD, and considerable evidence suggests that high HDL levels are associated with reduced CAA and lower neuroinflammation. (biomedcentral.com)
  • If your patient has a high HDL , the risk of CV disease tends to remain low, compared with low HDL at similar levels of risk," Miller told heart wire from Medscape. (medscape.com)
  • The serum PK level was positively correlated with HDL-C when its level was lower than 240 µg/mL and negatively correlated with HDL-C when its level was higher than 240 µg/mL. (bvsalud.org)
  • ORLANDO, Fla. (AP) - An experimental drug shows promise for raising HDL, or good cholesterol, which helps remove fats from the bloodstream. (rdworldonline.com)
  • We used think of HDL as protective because it grabs cholesterol from the bloodstream and other tissues and transports it to the liver, where it's recycled or disposed," says Dr. Jorge Plutzky, director of preventive cardiology at Harvard-affiliated Brigham and Women's Hospital. (harvard.edu)
  • We might hypothesize that HDL might still be an important biomarker of CVD in the group of relatively healthy patents in primary prevention. (medscape.com)
  • Persons with low high-density lipoprotein (HDL) cholesterol levels, except those patients with a deficiency syndrome, have no symptoms specific to the condition. (medscape.com)
  • Treatment for isolated low HDL cholesterol is provided mainly to patients with CHD and CHD risk equivalents. (medscape.com)
  • It's not uncommon to meet patients with isolated HDL-C, many of whom are young middle-aged men who are otherwise healthy and in good physical shape. (medscape.com)
  • A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks. (druglib.com)
  • Persons with the common low high-density lipoprotein (HDL) syndromes have no specific physical findings. (medscape.com)
  • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (medscape.com)
  • The predictive power of HDL-C is diminished when measures of either or both of the other markers are high. (medscape.com)
  • People with a high HDL should not be falsely reassured that their risk of heart disease is necessarily low. (medscape.com)
  • However, results from the AIM-HIGH and HPS2-THRIVE trials suggested that increasing HDL with niacin does not have much of an effect on CV risk. (medscape.com)
  • According to Tim Rolph, chief scientific officer for cardiovascular, metabolic and endocrine diseases research at Pfizer, we have known for a long time that high levels of HDL are associated with reduced cardiovascular risk. (chemistryworld.com)
  • Long touted as beneficial for heart health, high-density lipoprotein (HDL) is more complicated than once thought. (harvard.edu)
  • But the story of "good" high-density lipoprotein (HDL) is a bit more complex. (harvard.edu)
  • Danger from very high HDL? (harvard.edu)
  • However, a recent analysis found that people with very high HDL levels (80 mg/dL or higher) were about as likely to die from heart disease as people with low HDL (30 mg/dL or lower). (harvard.edu)
  • Just because an intervention raises HDL cholesterol, you can't assume risk of [heart attack] will be lower and it raises serious questions about whether HDL cholesterol can be used as a surrogate for heart attack risk in drug trials,' he says. (chemistryworld.com)
  • They simply lower cholesterol levels, which is assumed to contribute to better health. (healthimpactnews.com)
  • The other raised HDL levels but did not lower LDL levels at all. (healthimpactnews.com)
  • People who consumed the most sugar had HDL levels that were, on average, about 11 points lower than the low-sugar-intake group. (harvard.edu)
  • Unfortunately in the 1950's so called "heart healthy" polyunsaturated fats were recommended after discovering that they could lower cholesterol. (sallyanncreed.co.za)
  • There really is NO 'bad' cholesterol at all, and just by the way, anything you do to artificially lower your cholesterol is dangerous to your thyroid. (sallyanncreed.co.za)
  • The largest population-based heart disease study ever conducted showing clearly how 'bad cholesterol' rises in direct correlation to thyroid function. (sallyanncreed.co.za)
  • Other health habits could be at play, such as frequent alcohol intake, which is known to raise HDL and may increase heart attack risk (see "A daily drink: Not as harmless as you think" in the July 2022 Heart Letter ). (harvard.edu)
  • This has been addressed in a large mendelian randomisation study, recently published in The Lancet , looking at whether people with a specific gene that raises HDL levels are at a reduced risk of heart disease. (chemistryworld.com)
  • It also raises serious questions about whether HDL is a causal factor or not - it may merely be a good marker of future risk of disease. (chemistryworld.com)
  • The theory may be sound, based on a recent study conducted at the University of Pennsylvania showing the way the body processes cholesterol is as important as levels of good or bad cholesterol in predicting heart attack or other cardiovascular health risks. (upi.com)
  • But in the study group of 116,000 people with no difference in other risk factors, they found the risk of heart attack was exactly the same in those with the gene as those without, despite the difference in HDL cholesterol levels. (chemistryworld.com)
  • the level of HDL considered to be a significant risk factor was changed from less than 35 mg/dL to less than 40 mg/dL. (medscape.com)
  • In the present guidelines, low HDL cholesterol both modifies the goal for LDL-lowering therapy and is used as a risk factor to estimate 10-year risk for CHD. (medscape.com)
  • According to the study's executive summary, "Although clinical trial results suggest that raising HDL will reduce risk, the evidence is insufficient to specify a goal of therapy. (medscape.com)
  • A low HDL cholesterol level in this setting is rarely associated with an increased risk for premature CHD. (medscape.com)
  • If you have low HDL but everything else is normal, your risk of CV disease is not elevated," according to lead author Dr Michael Miller (University of Maryland School of Medicine, Baltimore). (medscape.com)
  • Dysfunctional HDL might be an important risk factor of CV disease with proatherogenic properties," he explained. (medscape.com)
  • However, we've never demonstrated that elevated HDL is actually the cause of the reduced risk,' he says. (chemistryworld.com)
  • My suspicion is that anacetrapib and evacetrapib will probably reduce the risk of disease, but largely because of their LDL-lowering properties. (chemistryworld.com)
  • For example, among people who smoke, quitting can raise HDL levels and is also known to markedly reduce cardiovascular risk. (harvard.edu)
  • For lowering your risk of heart attack and stroke, reducing elevated LDL cholesterol is still the main priority," says Dr. Plutzky. (harvard.edu)
  • According to the Residual Risk Reduction Initiative (R 3 i), residual CV risk is defined as the risk of CV events that persists in people despite achievement of treatment goals for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycaemia according to current standards of care. (biomedcentral.com)
  • Elevated LDL-cholesterol (LDL-C) levels are well-established to cause cardiovascular disease and several LDL-C-lowering therapies are clinically available to manage this vascular risk factor. (biomedcentral.com)
  • Researchers said the trial results suggest simply lowering bad cholesterol levels while increasing good cholesterol may not be enough to improve cardiovascular health. (upi.com)
  • Evacetrapib, development discontinued in 2015 due to insufficient efficacy. (wikipedia.org)
  • Traditionally, the things that doctors recommend to keep your heart healthy, such as exercising and eating a mostly plant-based diet, are also thought to boost HDL. (harvard.edu)
  • Cholesterol has NEVER been the cause of heart disease. (sallyanncreed.co.za)
  • In the same way cholesterol has NEVER (and I stress this) EVER been shown to cause heart disease or heart attacks. (sallyanncreed.co.za)
  • Cholesterol actually PROTECTS your heart and does the same for your thyroid. (sallyanncreed.co.za)
  • Hypothyroidism was first discovered to be a cause of heart attacks in 1890 but the blame shifted to cholesterol in about the 1930s. (sallyanncreed.co.za)
  • Endocrinologist and thyroid expert, Dr Broda Barnes had already shown through his hypothyroidism and heart disease research that low cholesterol diets made heart disease worse. (sallyanncreed.co.za)
  • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. (medscape.com)
  • As we close out the trial, we're trying to understand how a drug that seems to do all the right things in terms of blood cholesterol levels doesn't then translate into reducing clinical events. (upi.com)